Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| AN3-H5253 | Human | Human Angiopoietin-like 3 / ANGPTL3 Protein, Fc Tag |  |
|
|
| AN3-H52H3 | Human | Human Angiopoietin-like 3 / ANGPTL3 Protein, His Tag |  |
|
|
| AN3-M52H3 | Mouse | Mouse Angiopoietin-like 3 / ANGPTL3 Protein, His Tag |  |
|
|
| AN3-H82E7 | Human | Biotinylated Human Angiopoietin-like 3 / ANGPTL3 Protein, His,Avitag™ |  |
|
|
| AN3-H5226 | Human | Human Angiopoietin-like 3 / ANGPTL3 Protein, His Tag |  |
|
|
Immobilized Human Angiopoietin-like 3, His Tag (Cat. No. AN3-H52H3) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human ANGPTL3 Antibody, Human IgG1 with a linear range of 0.5-2 ng/mL (QC tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Evinacumab | REGN-1500 | Approved | Regeneron Pharmaceuticals Inc | Evkeeza | EU | Hypercholesterolemia | Ultragenyx Germany Gmbh | 2021-02-11 | Hypertriglyceridemia; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Metabolic Diseases | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| LNA-043 | LNA-043 | Phase 2 Clinical | Novartis Pharma Ag | Knee Injuries; Osteoarthritis, Knee; Osteoarthritis; Wounds and Injuries | Details |
| LY-3561774 | LY-3561774; DCR-CM-1; DCR-CM1 | Phase 2 Clinical | Dicerna Pharmaceuticals Inc | Metabolic Diseases; Dyslipidemias; Hyperlipoproteinemias; Cardiovascular Diseases; Lipid Metabolism Disorders | Details |
| Vupanorsen | ISIS-703802; PF-07285557 | Phase 2 Clinical | Ionis Pharmaceuticals Inc | Hypertriglyceridemia; Homozygous familial hypercholesterolemia; Diabetes Mellitus, Type 2; Non-alcoholic Fatty Liver Disease; Hyperlipoproteinemia Type I; Hyperlipoproteinemias; Dyslipidemias; Cardiovascular Diseases; Hyperlipoproteinemia Type II; Hyperlipidemias | Details |
| ARO-ANG3 | ARO-ANG3 | Phase 2 Clinical | Arrowhead Pharmaceuticals Inc | Homozygous familial hypercholesterolemia; Hypertriglyceridemia; Dyslipidemias; Hyperlipoproteinemia Type II | Details |
| ARO-APOC3 | ARO-APOC3 | Phase 3 Clinical | Arrowhead Pharmaceuticals Inc | Hypertriglyceridemia; Hyperlipoproteinemia Type I; Dyslipidemias | Details |
| LY-3475766 | LY-3475766 | Phase 1 Clinical | Eli Lilly And Company | Dyslipidemias | Details |
This web search service is supported by Google Inc.
A-Z
